EUVIMEDEUVIMED entdecken
Crossref

Enolase 1 inhibition potentiates sorafenib efficacy in hepatocellular carcinoma through ferroptosis induction

Qiu-Shuang Ma, Xiao-Man Zhao, Wan-Ying Zhang, Li-Jun Shao, Yi-Fan Liu, Li-Ya Feng, Xiao-Xia Yang, Xiu-Li Guo

Cellular Signalling · 2027-01 · 149 · 112916

DOI: 10.1016/j.cellsig.2026.112916 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2027-01. Verfasst von Qiu-Shuang Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Key Laboratory of Chemical Biology (Minis…. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Shandong Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enolase 1 (ENO1) is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor patient prognosis, as evidenced by TCGA and Kaplan-Meier (KM) analysis. This study demonstrates that targeting ENO1 with its specific inhibitor, ENOblock, markedly enhances the antitumor efficacy of sorafenib in HCC cells. The combination of sorafenib and ENOblock significantly suppresses cell proliferation, migration, invasion, and angiogenesis in vitro and in vivo. Mechanistically, sorafenib and ENOblock synergistically promote ferroptosis by concurrently regulating the Keap1/Nrf2/NQO1 and TFR1/C-MYC/NCOA4/FTH1/LC3 pathways, independent of xCT/GPX4 pathway. These effects are characterized by elevated levels of reactive oxygen species (ROS), iron ions, and malondialdehyde (MDA). In vivo tumorigenic models further confirm that the enhanced therapeutic effect of sorafenib by ENOblock. Our findings not only elucidate a novel ferroptosis-based mechanism underlying sorafenib response in HCC, but also position ENOblock-sorafenib combination as a promising preclinical proof- of-concept strategy targeting ENO1 for HCC intervention.

Schlagwörter

Stichwörter der Autor:innen

Drug resistanceEnolase 1FerroptosisHepatocellular carcinomaSorafenib

Autor:innen und Institutionen

  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmacology, School of Pharmaceutica…
  • Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, PR China. Electronic address: yxx_678@163.com.

Förderung

  • Shandong Province Natural Science Foundation

Zitieren

APA

Ma, Q. S., Zhao, X. M., Zhang, W. Y., Shao, L. J., Liu, Y. F., Feng, L. Y., Yang, X. X., & Guo, X. L. (2027). Enolase 1 inhibition potentiates sorafenib efficacy in hepatocellular carcinoma through ferroptosis induction. Cellular Signalling, 149, 112916. https://doi.org/10.1016/j.cellsig.2026.112916

Vancouver

Ma QS, Zhao XM, Zhang WY, Shao LJ, Liu YF, Feng LY, et al. Enolase 1 inhibition potentiates sorafenib efficacy in hepatocellular carcinoma through ferroptosis induction. Cellular Signalling. 2027;149:112916. doi:10.1016/j.cellsig.2026.112916

BibTeX
@article{Ma2027,
  author = {Ma, Qiu-Shuang and Zhao, Xiao-Man and Zhang, Wan-Ying and Shao, Li-Jun and Liu, Yi-Fan and Feng, Li-Ya and Yang, Xiao-Xia and Guo, Xiu-Li},
  title = {Enolase 1 inhibition potentiates sorafenib efficacy in hepatocellular carcinoma through ferroptosis induction},
  journal = {Cellular Signalling},
  year = {2027},
  volume = {149},
  pages = {112916},
  doi = {10.1016/j.cellsig.2026.112916}
}
Kostenlos starten →